With a phase II trial in stubborn triple-negative breast cancer (TNBC) set to begin soon and results already disclosed against nuclear protein in testis (NUT) midline carcinoma, bromodomain and extra terminal domain (BET) inhibitor specialist Tensha Therapeutics Inc. drew Roche AG to the table for a takeover valued at up to $535 million.